Technical Analysis for IMRN - Immuron Limited
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| F | 1.95 | 1.66% | 0.03 |
Earnings due: Nov 19
*** please verify all earnings dates ***| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Flat |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 20 DMA Resistance | Bearish | 0.00% | |
| Shooting Star Candlestick | Bearish | 0.00% | |
| Lizard Bearish | Bearish Day Trade Setup | 0.00% | |
| Pocket Pivot | Bullish Swing Setup | 0.00% | |
| Volume Surge | Other | 0.00% | |
| MACD Bullish Signal Line Cross | Bullish | 1.66% | |
| NR7 | Range Contraction | 1.66% | |
| Narrow Range Bar | Range Contraction | 1.66% | |
| Wide Bands | Range Expansion | 1.66% | |
| Oversold Stochastic | Weakness | 1.66% |
| Alert | Time |
|---|---|
| Rose Above Previous Day's High | about 23 hours ago |
| 20 DMA Resistance | about 23 hours ago |
| 10 DMA Resistance | about 23 hours ago |
| 2x Volume Pace | about 23 hours ago |
| 1.5x Volume Pace | about 23 hours ago |
Get a Trading Sidekick!
- Earnings date: 11/19/2024
Immuron Limited Description
Immuron Limited, a microbiome company, focuses on developing and commercializing oral immunotherapeutics for the treatment of various gut medicated diseases in Australia and internationally. The company operates through Research and Development, and HyperImmune Products segments. It has a technology platform that enables a shorter development therapeutic cycle. The company markets and sells Travelan for the prevention of travellersÂ’ diarrhea. Its lead product candidate IMM-124E is in Phase 2b clinical trials for NASH and ASH. The company also has other preclinical immunotherapy pipeline products targeting immune-related diseases. Immuron Limited has a research and development collaboration agreement with the Walter Reed Army Institute of Research (WRAIR) for the development of a Shigella vaccine; and Naval Medical Research Center for the testing of Travelan in cell lines of campylobacter and enterotoxigenic escherichia coli. The company was founded in 1994 and is based in Blackburn North, Australia.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Disease Immunotherapy Medical Research Microbiology Diarrhea Bacteria Gram Negative Bacteria Immunotherapeutics Tropical Diseases Immune Related Diseases Shigella
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 5.96 |
| 52 Week Low | 1.481 |
| Average Volume | 7,604 |
| 200-Day Moving Average | 2.35 |
| 50-Day Moving Average | 2.42 |
| 20-Day Moving Average | 2.03 |
| 10-Day Moving Average | 1.94 |
| Average True Range | 0.14 |
| RSI (14) | 35.48 |
| ADX | 13.05 |
| +DI | 23.98 |
| -DI | 17.69 |
| Chandelier Exit (Long, 3 ATRs) | 2.31 |
| Chandelier Exit (Short, 3 ATRs) | 2.23 |
| Upper Bollinger Bands | 2.32 |
| Lower Bollinger Band | 1.74 |
| Percent B (%b) | 0.36 |
| BandWidth | 28.51 |
| MACD Line | -0.15 |
| MACD Signal Line | -0.16 |
| MACD Histogram | 0.0095 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 2.24 | ||||
| Resistance 3 (R3) | 2.26 | 2.18 | 2.19 | ||
| Resistance 2 (R2) | 2.18 | 2.11 | 2.17 | 2.17 | |
| Resistance 1 (R1) | 2.07 | 2.07 | 2.13 | 2.05 | 2.16 |
| Pivot Point | 1.99 | 1.99 | 2.02 | 1.98 | 1.99 |
| Support 1 (S1) | 1.88 | 1.92 | 1.94 | 1.86 | 1.75 |
| Support 2 (S2) | 1.80 | 1.88 | 1.79 | 1.73 | |
| Support 3 (S3) | 1.69 | 1.80 | 1.71 | ||
| Support 4 (S4) | 1.67 |
